Clinical Trials Appendix Q4 2022 Results Update Upcoming pipeline catalysts: 2023 and 2024 Oncology BioPharmaceuticals Rare Disease H1 2023 H2 2023 2024 Regulatory decision Imfinzi + Imjudo - hepatocellular carcinoma (1L) (HIMALAYA) (EU) Imfinzi +/- Imjudo - NSCLC (1L) (POSEIDON) (EU) Lynparza - prostate cancer (1L) (PROpel) (US, JP) Enhertu - HER2+ breast cancer (2L) (DESTINY-Breast03) (CN) Enhertu - HER2-low breast cancer (3L) (DESTINY-Breast04) (JP) Farxiga - HFpEF (DELIVER) (US) Beyfortus - respiratory syncytial virus (US) Ultomiris - NMOSD (CHAMPION-NMOSD) Enhertu - HER2m NSCLC (2L+) (DESTINY-Lung01) (EU, JP) Enhertu - HER2-low breast cancer (3L) (DESTINY-Breast04) (CN) Calquence - CLL (ASCEND) (CN) Forxiga - HFpEF (DELIVER) (CN) Soliris - gMG (CN) Soliris - NMOSD (CN) Koselugo - NF1-PN (SPRINT) (CN) Regulatory submission and/or acceptance Lynparza - gBRCA breast cancer (adjuvant) (OlympiA) (CN) Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)capivasertib - HR+/HER2- breast cancer (1L) (CAPItello-291)Dato-DXd - NSCLC (3L) (TROPION-Lung01) eplontersen - hATTR-PN(NEURO-TTRansform) (US) Beyfortus - respiratory syncytial virus (JP, CN) Evusheld - COVID-19 (TACKLE/PROVENT) (CN) danicopan - PNH with extravascular haemolysis Tagrisso - EGFRm NSCLC (1L) (FLAURA2) Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA) Imfinzi - NSCLC (neoadjuvant) (AEGEAN) Imfinzi - liver cancer (adjuvant) (EMERALD-2)Imfinzi - bladder cancer (muscle invasive) (NIAGARA) Imfinzi - biliary tract cancer (TOPAZ-1) (CN) Imfinzi - bladder cancer (1L) (NILE) capivasertib - TNBC (locally adv./met.) (CAPItello-290)AZD3152 - prevention of COVID-19 (SUPERNOVA) ALXN1840 - Wilson disease Tagrisso - EGFRm NSCLC (resectable, Stg. II/III) (NeoADAURA) Calquence - MCL (1L) (ECHO) Imfinzi + Imjudo - hepatocellular carcinoma (1L) (HIMALAYA) (CN) camizestrant - HR+/HER2-neg breast cancer (SERENA-6) Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2) roxadustat - anaemia of myelodysplastic syndrome) Imfinzi - liver cancer (locoregional) (EMERALD-1) tozorakimab - acute respiratory failure (TILIA) Imfinzi - SCLC (limited-stage) (ADRIATIC) Breztri - severe asthma (KALOS) Lynparza - ovarian cancer (1L) (DUO-O) Breztri - severe asthma (LOGOS) Lynparza - endometrial cancer (1L) (DUO-E) Fasenra - bullous pemphigoid (FJORD) Lynparza - prostate cancer (1L) (PROpel) (CN) Fasenra - EGPA (MANDARA) Enhertu - HER2+/HER2low gastric 3L (DESTINY-Gastric01) (CN) Fasenra - HES (NATRON) Enhertu - HER2+ gastric (2L) (DESTINY-Gastric04) acoramidis - ATTR-CM(ALXN2060-TAC-302) Enhertu - HER2-low breast cancer (2L) (DESTINY-Breast06) anselamimab - AL amyloidosis (CAEL101-302) Enhertu - High-risk HER2+ early breast cancer (non-met.) (DESTINY-Breast11) Key Phase III data readouts Tagrisso - EGFRm NSCLC (1L) (FLAURA2) Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA) Tagrisso - EGFRm NSCLC (resectable, Stg. II/III) (NeoADAURA) Fasenra - CRwNP (ORCHID) Imfinzi - NSCLC (neoadjuvant) (AEGEAN) Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2) Lynparza - PARP 1L BRCAwt ovarian cancer (MONO-OLA1) Fasenra - bullous pemphigoid (FJORD) Lynparza - ovarian cancer (1L) (DUO-O) Imfinzi - SCLC (limited-stage)(ADRIATIC) Enhertu - High-risk HER2+ early breast cancer (non-met.) Saphnelo - moderate to severe SLE (TULIP-SC) Dato-DXd - NSCLC (3L) (TROPION-Lung01) Imfinzi - liver cancer (locoregional) (EMERALD-1) (DESTINY-Breast11) Tezspire - chronic rhinosinusitis with nasal polyps roxadustat - anaemia of myelodysplastic syndrome Imfinzi - liver cancer (adjuvant) (EMERALD-2) Enhertu - HER2+ gastric (2L) (DESTINY-Gastric04) (WAYPOINT) Imfinzi - bladder cancer (muscle invasive) (NIAGARA) Calquence - MCL (1L) (ECHO) Tezspire - severe asthma (DIRECTION) Imfinzi - bladder cancer (1L) (NILE) Orpathys - NSCLC with MET exon 14 mutations (locally adv./met.) Ultomiris - HSCT-TMA (ALXN1210-TM-313) Lynparza - endometrial cancer (1L) (DUO-E) camizestrant - HR+/HER2- breast cancer (SERENA-6) Ultomiris - paedeatric HSCT-TMA(ALXN1210-TM-314) Enhertu - HER2-low breast cancer (2L) (DESTINY-Breast06) Dato-DXd - TNBC (locally recurrent inop./met.) Koselugo - NF1-PN (KOMET) capivasertib - TNBC (locally adv./met.) (CAPItello-290) (TROPION-Breast02) acoramidis - ATTR-CM (ALXN2060-TAC-302) Farxiga - myocardial infarction (DAPA-MI) tozorakimab - acute respiratory failure (TILIA) anselamimab - AL amyloidosis (CAEL101-302) Fasenra - EGPA (MANDARA) Breztri - severe asthma (KALOS) Fasenra - HES (NATRON) Breztri - severe asthma (LOGOS) AZD3152 - prevention of COVID-19(SUPERNOVA) 2 Appendix: Glossary. Clinical Trials Appendix: selected highlights Approved medicines: key LCM Next-wave pipeline BioPharmaceuticals Oncology Rare Disease Dato-DXd (TROP2 ADC) tozorakimab (IL-33) volrustomig (PD-1/CTLA-4) AZD3152 (COVID-19 LAAB) vemircopan (oral Factor D) capivasertib (AKT) eplontersen (LICA) gefurulimab (C5 mini-body) camizestrant (ngSERD) mitiperstat (MPO) ALXN1850 (ngHPP) rilvegostomig (PD-1/TIGIT) cotadutide (GLP-1/glucagon) AZD5305 (PARP-1sel) 3 Appendix: Glossary. Movements since Q3 2022 update New to Phase I New to Phase II New to Pivotal trial New to registration NME NME NME AZD0186# MEDI1341# AZD3152¶ GLP-1R agonism type-2 diabetes alpha synuclein mAb multiple system SARS-CoV-2 LAAB prevention of COVID-19 atrophy/Parkinson's disease AZD6793 ceralasertib + Imfinzi LATIFY# IRAK4 inhibitor inflammatory diseases rilvegostomig (AZD2936) ARTEMIDE-1# ATR inhibitor + PDL-1 mAb non-small cell lung PD-1/TIGIT bispecific mAb solid tumours cancer AZD9592 EGFR/cMET solid tumours Additional indication gefurulimab mitiperstat# humanised bispecific VHH antibody generalised myeloperoxidase COPD myasthenia gravis mitiperstat# Additional indication myeloperoxidase NASH tozorakimab IL-33 mAb acute respiratory failure datopotamab deructucan AVANZAR# TROP2 ADC 1L NSCLC, squamous and non- squamous 1L NSCLC, TROP2 BM+ Dato-DXd TROPION Lung07# TROP2 ADC 1L NSCLC PD-L1 <50% non-squamous Dato-DXdTROPION-Breast03# TROP2 ADC adjuvant residual disease triple negative breast cancer Phase progressions based on first patient dose achievement. 4 #Partnered and/or in collaboration ¶Registrational Phase I/III trial Appendix: Glossary. Movements since Q3 2022 update Removed from Phase I Removed from Phase II Removed from Phase III Removed from registration NME NME Life-cycle management NME AZD8701 +/- Imfinzi# navafenterol# Fasenra HUDSON Airsupra (PT027)#2 FOXP3 +/- PD-L1 mAb solid tumours MABA chronic obstructive pulmonary IL-5R mAb eosinophilic gastritis and ICS/SABA asthma disease eosinophilic gastroenteritis MEDI9253 Life-cycle management rNDV IL-12 solid tumours Additional indication Imfinzi PEARL# Farxiga/Forxiga DELIVER2 tozorakimab PD-L1 mAb 1st-line metastatic non-small cell SGLT2 inhibitor worsening HF or CV death in IL-33 mAb atopic dermatitis lung cancer patients with chronic heart failure Life-cycle management Imfinzi +/- Imjudo + CTx POSEIDON#2 Fasenra ARROYO PD-L1 mAb +/- CTLA-4 mAb + CTx 1st-line non- IL-5R mAb chronic spontaneous urticaria small cell lung cancer Lynparza + abiraterone PROpel#2 PARP inhibitor + NHA prostate cancer Phase progressions based on first patient dose achievement. 5 2Approved #Partnered and/or in collaboration Appendix: Glossary. This is an excerpt of the original content. To continue reading it, access the original document here. Attachments Original Link Original Document Permalink Disclaimer AstraZeneca plc published this content on 09 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2023 07:12:40 UTC.